DR5 Governs Compound Exocytosis in Colonic Goblet Cells via TATA‐Box Binding Protein‐Dependent Bestrophin‐2 Transcriptional Regulation
Authors:
Open Access
- 11 November 2025
- journal article
- Published by Wiley in Advanced Science
- Vol. 13 (6) , e16789
Abstract
The colonic mucus barrier, dependent on goblet cell‐secreted mucin2 (Muc2), prevents microbial invasion. Compound exocytosis enables the rapid, high‐volume release of mucus from goblet cells; its underlying mechanisms, however, remain unclear. Here, death receptor 5 (DR5) is identified as a critical regulator of this process. Knockout of DR5 exhibits a thinner mucus layer despite elevated Muc2 and enlarged granules, causing mild dysbiosis and enhances susceptibility to Citrobacter rodentium . DR5 knockout and its ligand TRAIL knockdown inhibits carbachol‐triggered goblet cell compound exocytosis, while DR5‐activator Bioymifi potentiates it. DR5 modulates intracellular pH through the colonic goblet cell‐expressed HCO 3 − channel Bestrophin‐2 (Best2). TRAIL/DR5/Best2 co‐localize in goblet cells, and Best2 knockdown abolishes DR5's pro‐exocytosis effect. Proteomics and bioinformatic analyses implicate TATA‐box binding protein (TBP) in the death domain‐dependent transcriptional regulation of Best2 by DR5. This is supported by TBP‐ BEST2 promoter binding, as well as enhanced BEST2 mRNA expression and promoter activity upon TBP overexpression. DR5 knockout suppresses TBP expression in colonic goblet cells, while activation increases it. Moreover, TBP knockdown abrogates Bioymifi‐enhanced Best2 expression and compound exocytosis. The findings demonstrate that disruption of the DR5‐TBP‐Best2 axis in goblet cells perturbs goblet cell compound exocytosis and mucus layer formation, resulting in dysbiosis and heightened infection susceptibility.Keywords
Funding Information
- National Natural Science Foundation of China (82270576)
This publication has 65 references indexed in Scilit:
- The anion exchanger slc26a3 regulates colonic mucus expansion during steady state and in response to prostaglandin E2, while Cftr regulates de novo mucus release in response to carbamylcholinePflügers Archiv - European Journal of Physiology, 2024
- Smart Tumor Microenvironment-Responsive Nano-Prodrug for Disulfiram Toxification In Situ and the Exploration of Lethal Mechanisms in CellsLangmuir, 2021
- MUC2 and related bacterial factors: Therapeutic targets for ulcerative colitisEBioMedicine, 2021
- Influence of TRAIL Deficiency on Th17 Cells and Colonic Microbiota in Experimental Colitis Mouse ModelThe American Journal of the Medical Sciences, 2021
- A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen SusceptibilityCell, 2016
- Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancerCellular and Molecular Life Sciences, 2016
- New developments in goblet cell mucus secretion and functionMucosal Immunology, 2015
- Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2Cell Death & Disease, 2014
- Small-molecule activation of the TRAIL receptor DR5 in human cancer cellsNature Chemical Biology, 2012
- FADD/MORT1 and Caspase-8 Are Recruited to TRAIL Receptors 1 and 2 and Are Essential for Apoptosis Mediated by TRAIL Receptor 2Immunity, 2000